---
title: >-
  Impact of Therapeutic Inertia on Patient-Reported Outcomes in
  Moderate-to-Severe Atopic Dermatitis: A 12-Month Longitudinal Study from the
  TARGET-DERM AD Registry (RAD Winter 2023)
description: >-
  Explore this publication on real-world evidence: Impact of Therapeutic Inertia
  on Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis: A…
date: '2024-01-01'
author: Keith D. Knapp, Breda Munoz, Julie M. Crawford
category: Publications
tags:
  - Atopic Dermatitis (AD)
  - Pharma Partner
  - 'Yes'
  - R&D
  - AbbVie Inc.
  - El Paso Dermatology
  - Care
  - George Washington University
  - Health System Partner
  - Poster Presentation
  - Dermatology
  - RAD Winter Conference
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/di-atopic-dermatitis/impact-of-therapeutic-inertia-on-patient-reported-outcomes/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: impact-of-therapeutic-inertia-on-patient-reported-outcomes
id: 6FrJVJUQnMFI9n4lQRQhb2
contentType: article
---

## Challenge

This is a RAD Winter 2023 presentation of the same therapeutic inertia PRO study as Row 22 (Fall Clinical 2024). Earlier version of the analysis with the same core finding — a significant proportion of patients fail to achieve PRO targets with systemic therapy over 12 months without treatment escalation.

## Solution

TARGET-DERM AD registry used to track PRO trajectories in patients not meeting AHEAD targets at 3–12 months post-systemic therapy initiation, quantifying the patient-reported burden of therapeutic inertia.

## Impact

Multi-venue dissemination of the therapeutic inertia PRO findings broadens the evidence base for prescriber education and treatment escalation advocacy across key AD scientific communities.

## Use Cases / Links

Multi-venue dissemination of therapeutic inertia PRO burden evidence for AD prescriber education, Real-world PRO consequences of undertreated AD for treat-to-target advocacy across AD communities, Evidence supporting timely treatment escalation in moderate-to-severe AD management